Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study

Area of Science:

• Neuroscience
• Biochemistry
• Radiology

Background:

• Glutamate (Glu) is a key neurotransmitter implicated in excitotoxic cell damage.
• Excitotoxicity is a significant factor in Alzheimer's disease (AD) pathogenesis.
• Memantine is known to modulate glutamate-induced excitotoxicity, but its effect on in vivo brain glutamate levels remains uncharacterized.

Purpose of the Study:

• To investigate the influence of memantine on in vivo hippocampal glutamate levels.
• To assess changes in glutamate levels before and after memantine treatment in cognitively impaired individuals.
• To compare these changes with a non-treated control group.

Main Methods:

• Proton magnetic resonance spectroscopy (3 T) was used to measure hippocampal Glu levels.
• High spatial resolution (0.5 cm³ voxels) was employed for precise measurements.
• Measurements were taken in cognitively impaired and normal individuals before and after 6 months of memantine treatment, and in a non-treated control group.

Main Results:

• Memantine treatment led to a decrease in the glutamate/creatine (Glu/Cr) ratio in the left hippocampal region.
• A reduction in hippocampal glutamate levels was observed following memantine administration.
• No significant changes were noted in the non-treated control group.

Conclusions:

• Memantine effectively reduces hippocampal glutamate levels in individuals with cognitive impairment.
• The observed reduction in glutamate is consistent with memantine's proposed anti-excitotoxic mechanism of action.
• These findings provide in vivo evidence supporting memantine's role in managing excitotoxicity in Alzheimer's disease.